deltatrials
Terminated PHASE3 INTERVENTIONAL 3-arm NCT04591808

Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia

Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia, 8 Weeks, Phase 3, Randomized, Double-blind, Active-control, Multinational, Multi-center, Parallel Study

Sponsor: ADIR, a Servier Group company

Updated 11 times since 2020 Last updated: Oct 17, 2023 Started: Sep 9, 2021 Primary completion: Apr 8, 2022 Completion: Apr 8, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

for strategic reasons

Other Dyslipidemias trials with similar outcome

Browse all Dyslipidemias trials

Listed as NCT04591808, this PHASE3 trial focuses on Dyslipidemias and Hypertension and remains terminated or withdrawn. Sponsored by ADIR, a Servier Group company, it has been updated 11 times since 2021, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotNot Yet Recruiting~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~May 2022 · 5 months · monthly snapshot~May 2022 – ~Jan 2023 · 8 months · monthly snapshotActive Not Recruiting~Jan 2023 – ~May 2023 · 4 months · monthly snapshot~May 2023 – ~Nov 2023 · 6 months · monthly snapshotTerminated~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

11 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE3

  5. May 2023 — Nov 2023 [monthly]

    Terminated PHASE3

Show 6 earlier versions
  1. Jan 2023 — May 2023 [monthly]

    Terminated PHASE3

    Status: Active Not RecruitingTerminated

  2. May 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  3. Dec 2021 — May 2022 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  4. Sep 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE3

  5. Jan 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE3

  6. Nov 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ADIR, a Servier Group company
  • Institut de Recherches Internationales Servier
Data source: Servier

For direct contact, visit the study record on ClinicalTrials.gov .